The 25th anniversary of the Eurotransplant Acceptable Mismatch program for highly sensitized patients.
In 2014, the Eurotransplant Acceptable Mismatch (AM) program celebrated its 25th anniversary. The AM program was initiated to enhance transplantation of highly sensitized patients awaiting a renal transplant within the Eurotransplant region. Unlike the regular renal transplant allocation, in which the histocompatibility parameters consist of the degree of compatibility with the patient's human leucocyte antigen (HLA) type and the absence of unacceptable antigens, the AM program is based on compatibility of the possible donor with the combination of the patient's HLA type and the acceptable antigens. These acceptable antigens are defined as HLA antigens to which the patient has never made antibodies. This strategy aims at the prediction of a negative cross match. Since the start of the program almost 2000 patients participated and more than 1000 patients were transplanted with excellent transplant outcome, comparable to that of non-immunized transplant recipients within Eurotransplant. Progressive insights have led to fine-tuning of the AM program through the years, as well as to novel initiatives, including a recent consortium study to determine the feasibility of a Europe-wide AM program. The current review will tell the story of the AM program in a historical perspective, but will also provide an open-minded look into the future of transplanting highly sensitized patients.